Circular Genomics raised $15 million in a Series A round led by Mountain Group Partners to advance a circular RNA (circRNA)‑based biomarker platform for early detection of Alzheimer’s disease. The San Diego spinout, working with collaborators at Washington University, highlighted a circRNA signature anchored by circHOMER1 and plans to use proceeds for clinical validation and commercialization. Circular RNAs are covalently closed RNA molecules that can be enriched in extracellular fluids; the company positions them as stable, brain‑derived signals detectable in blood. The financing will support larger validation cohorts and exploratory expansion into other neurodegenerative and psychiatric indications. Investors include Poplar Grove, HIP Fund and the Alzheimer’s Drug Discovery Foundation. The raise underscores growing interest in molecular biomarkers for neurology and the race to develop noninvasive tests for early‑stage neurodegeneration. Circular Genomics will next focus on analytical validation, regulatory strategy and partnerships with diagnostic service providers.